The Rise of the Payer

Summary

Over the past 15 years, arguably the most significant force reshaping healthcare marketing has been the rise of the payer customer. Once seen as an administrative hurdle or a back-office cost center, payers have emerged as power players with heavy influence over healthcare consumption and delivery. Their growing clout has altered prescribing and treatment patterns and reshaped advertising priorities for manufacturers, making value-based narratives and tailored communications more critical than ever.

Here are some key milestones in the rise of payer influence:

Following the global financial crisis of 2008, consumer-directed and high-deductible health plans (HDHPs) started gaining traction as employers sought to manage healthcare costs and provide cost transparency through sharing liability. This created a shift in patient behaviors, with more individuals weighing costs against care, leading manufacturers to rethink advertising strategies. Suddenly, it wasn’t just about targeting prescribers—it was also about educating patients on value and affordability.

While still in their infancy, the push toward value-based care models began to take shape. Payers started experimenting with quality-based contracts and early risk-sharing models, forcing manufacturers to invest in real-world evidence (RWE) and health economics and outcomes research (HEOR) to demonstrate their products’ value.

While representing a relatively small proportion of drug claims, specialty drugs surpassed 50% of total drug spending during this period, giving payers more leverage to demand aggressive rebates and discounts. Advances in genomic research and precision medicine and the rise of biologics as treatment mainstays, particularly in oncology and immunology, amplified this trend.

The FDA’s approval of biosimilars provided payers with powerful tools to challenge the high costs of branded biologics. These lower-cost alternatives quickly became negotiation levers, pressuring manufacturers to defend their pricing and value propositions, and data analytics emerged as a meaningful communications tool.

The Inflation Reduction Act (IRA) introduced the first transformative changes to the Medicare Part D program since its inception, including the requirement for CMS to negotiate certain drug prices and placing a cap on out-of-pocket Part D costs for beneficiaries. These reforms marked a shift toward direct government intervention in pricing and access, amplifying the need for manufacturers to engage in proactive payer communication.

Telemedicine and digital health tools became permanent fixtures in care delivery, creating new opportunities and challenges for manufacturers. Payers increasingly expected manufacturers to integrate digital health solutions into their offerings, further blurring the lines between product and service. At the same time, use of real-world evidence was on the rise, with manufacturers leveraging data from electronic health records, wearables, and digital patient-reported outcomes to inform market access decisions.

Social determinants of health (SDOH) emerged as a focal point for payers, who sought to address non-medical barriers to care. Manufacturers began aligning their messaging with these efforts, emphasizing how their products supported equitable access and improved outcomes for underserved populations. Over this dynamic period, manufacturers increasingly needed to communicate not only clinical differentiation but also economic and societal value—marking the beginning of a more data-driven and payer-conscious approach. Payers now actively shape treatment decisions, access pathways, and pricing dynamics. The continued rise of specialty drugs, the acceleration of digital health, and growing policy reforms will ensure that the payer’s influence remains a driving force in healthcare—and that advertising will continue to evolve in response.